Menu
New generation of precision medicine in immuno-oncology, with proprietary STC platform, designed to generate first-in-class, proteomic-driven cancer vaccines.
Anticipating tumor’s evolution in cold solid tumors, which is currently the biggest unmet need in oncology
Of patients currently undergoing treatment for solid tumors will experience treatment failure and relapse within the 5 years.
In 2022, 10 million patients suffering from solid tumors found themselves in a therapeutic impasse leading to their death.
This figure is set to rise by 70% by 2045.
is designed to generate ‘first-in-class’, off-the-shelf
therapeutic cancer vaccine fighting cancer recurrence.
CHARACTERIZED BY MULTI-OMICS ANALYSIS
REGARDLESS OF THEIR EVOLUTION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
It’s a wrap San Diego! 🇺🇸 We are leaving #BIO2024 after a
📢 𝗢𝗻𝗰𝗼𝗦𝘁𝗮𝗿𝘁𝘂𝗽 𝗦𝘂𝗺𝗺𝗶𝘁 ! Tout juste rentré du BIO, Paul Bravetti sera
We are excited to highlight the graduates of the CDL-Global #AdvancedTherapies and
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
We are backed by internationally recognized key scientific opinion leaders. They act as strategic advisors to ensure validation process robustness, and as main ambassadors of our technology, significantly contributing to our publications.
Our team is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients.
With the support of
The efficacy of current approaches is compromised by no anticipating tumor plasticity and resistances mechanisms and must be combined to be efficient.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
